Autoimmune Gastritis Market
DelveInsight's "Autoimmune Gastritis Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Autoimmune Gastritis, historical and forecasted epidemiology as well as the Autoimmune Gastritis (AIG)market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom and Japan.
The Autoimmune Gastritis (AIG) market report provides current treatment practices, emerging drugs, Autoimmune Gastritis (AIG) market share of the individual therapies, current and forecasted Autoimmune Gastritis (AIG) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Autoimmune Gastritis (AIG) treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, Spain)and the United Kingdom
- Japan
Study Period: 2019–2032
Autoimmune Gastritis Treatment Algorithm and Disease Understanding
The DelveInsight’s Autoimmune Gastritis market report gives a thorough understanding of Autoimmune Gastritis (AIG) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Autoimmune Gastritis (AIG) is a subtype of chronic gastritis in which gastric parietal cells are destroyed by the production of autoantibodies against the proton pump located in parietal cells. Histologically, AIG falls under the umbrella “atrophic gastritis,” which comprises several conditions where the downstream histologic consequence of chronic environmental (e.g. H. pylori) or non-environmental triggers is gastric atrophy, that is, the disappearance of the native gastric glands and thinning of the mucosa.
AIG is most often asymptomatic. The symptoms are usually nonspecific, with patients most commonly reporting dyspepsia, especially post-prandial distress. Extra-gastrointestinal symptoms include several other organ systems. Vitamin B12 deficiency can lead to sub-acute combined degeneration, peripheral neuropathy and myelopathy of the posterior and lateral columns that can be irreversible if treatment is delayed. In severe cases, this can also cause optic neuropathy and encephalopathy.
Autoimmune Gastritis Diagnosis
Diagnosis can be made through a combination of clinical findings such as certain blood tests and the presence of other autoimmune conditions and biopsy of the stomach lining. Serologic testing for autoantibodies may or may not be used clinically as an adjunct for diagnosis.
Autoimmune Gastritis Treatment
The treatment of autoimmune atrophic gastritis is generally focused on preventing or correcting vitamin B12 and iron deficiencies. The condition in which pernicious anemia is already present at the time of diagnosis, vitamin B12 shots (injections) may be recommended. Dietary and oral supplements are the most recommended treatment for AIG.
Early supplementation with B12 and iron may prevent anemia and neurological problems. Probiotics and Gut Rebuilding Nutrients (Glutamine and N-Acetyl-Cysteine) are generally used to correct the condition.
Autoimmune Gastritis Epidemiology
The Autoimmune Gastritis epidemiology section provides insights about historical and current Autoimmune Gastritis (AIG) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
According to by Coati et al. (2015), its prevalence has been estimated to vary between 2% and 5% in the general population. These estimates change depending on the epidemiological context, comorbidities and patient selection.
The disease epidemiology covered in the report provides historical as well as forecasted Autoimmune Gastritis (AIG) epidemiology [segmented as Total Prevalent Cases of Autoimmune Gastritis, Gender-specific Prevalent cases of Autoimmune Gastritis, and Diagnosed and Treatable cases of Autoimmune Gastritis in the 7MM covering the United States EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country Wise- Autoimmune Gastritis Epidemiology
This section provides glimpse of the Autoimmune Gastritis epidemiology in the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan.
Autoimmune Gastritis Drug Chapters
The drug chapter segment of the Autoimmune Gastritis (AIG) report encloses the detailed analysis of Autoimmune Gastritis (AIG) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Autoimmune Gastritis (AIG) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Autoimmune Gastritis Emerging Drugs
Marinomed Biotech AG, a Vienna-based biopharmaceutical company, is developing a groundbreaking treatment for autoimmune gastritis together with the Medical University of Vienna. Aided by the Marinosolv technology platform, the development is focused on an anti-inflammatory treatment rather than treating only the deficiency symptoms. “The goal of Marinomed is to solve the unsolvable using Marinosolv.
Note: Detailed emerging therapies assessment will be provided in the full report of Autoimmune Gastritis
Autoimmune Gastritis (AIG) Market Outlook
- The treatment of autoimmune atrophic gastritis is generally focused on preventing or correcting vitamin B12 and iron deficiencies. The condition in which pernicious anemia is already present at the time of diagnosis, vitamin B12 shots (injections) may be recommended.
- Early supplementation with B12 and iron may prevent anemia and neurological problems. Probiotics and Gut Rebuilding Nutrients (Glutamine and N-Acetyl-Cysteine) are generally used to correct the condition.
- People with autoimmune gastritis can also be deficient in folic acid, another B vitamin. In this case, folic acid-containing supplements are given to patients.
- Key players such as Marinomed Biotech along with few others are involved in developing therapies for Autoimmune Gastritis.
- According to DelveInsight, Autoimmune Gastritis (AIG) market in 7MM is expected to witness a major change in the study period 2019-2032.
Analyst Commentary
- The pipeline of Autoimmune Gastritis (AIG) is very robust, many potential therapies are being investigated for the treatment of Autoimmune Gastritis, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
- The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Autoimmune Gastritis (AIG) market in the 7MM. Aside from that, the market size of Autoimmune Gastritis (AIG) may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
- The market growth of Autoimmune Gastritis (AIG) may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Autoimmune Gastritis (AIG) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Autoimmune Gastritis (AIG) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Autoimmune Gastritis (AIG) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: Detailed emerging therapies assessment will be provided in full report of HER2+ Breast Cancer.
Autoimmune Gastritis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Autoimmune Gastritis (AIG) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Autoimmune Gastritis (AIG) emerging therapies.
Reimbursement Scenario in Autoimmune Gastritis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Autoimmune Gastritis (AIG) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Autoimmune Gastritis (AIG) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Autoimmune Gastritis (AIG) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Autoimmune Gastritis (AIG), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Autoimmune Gastritis (AIG) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Autoimmune Gastritis (AIG) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Autoimmune Gastritis (AIG) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Autoimmune Gastritis (AIG) market
Report Highlights
- In the coming years, the Autoimmune Gastritis (AIG) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Autoimmune Gastritis (AIG) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Autoimmune Gastritis. The launch of emerging therapies will significantly impact the Autoimmune Gastritis (AIG) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Autoimmune Gastritis
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Autoimmune Gastritis (AIG) Report Insights
- Autoimmune Gastritis Patient Population
- Autoimmune Gastritis Therapeutic Approaches
- Autoimmune Gastritis Pipeline Analysis
- Autoimmune Gastritis Market Size and Trends
- Autoimmune Gastritis Market Opportunities
- Impact of upcoming Autoimmune Gastritis Therapies
Autoimmune Gastritis Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Autoimmune Gastritis (AIG) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Autoimmune Gastritis Drugs Uptake
Autoimmune Gastritis (AIG) Report Assessment
- Current Autoimmune Gastritis Treatment Practices
- Autoimmune Gastritis Unmet Needs
- Autoimmune Gastritis Pipeline Product Profiles
- Autoimmune Gastritis Market Attractiveness
Key Questions Answered In The Autoimmune Gastritis Market Report
Autoimmune Gastritis Market Insights:
- What was the Autoimmune Gastritis (AIG) drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Autoimmune Gastritis (AIG) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest Autoimmune Gastritis (AIG) market size during the forecast period (2019-2032)?
- At what CAGR, the Autoimmune Gastritis (AIG) market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Autoimmune Gastritis (AIG) market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Autoimmune Gastritis (AIG) market growth till 2032, and what will be the resultant market Size in the year 2032?
How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Autoimmune Gastritis Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Autoimmune Gastritis?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
- What is the historical Autoimmune Gastritis (AIG) patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
- What would be the forecasted patient pool of Autoimmune Gastritis (AIG) in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Autoimmune Gastritis?
- Out of all 7MM countries, which country would have the highest prevalent population of Autoimmune Gastritis (AIG) during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Autoimmune Gastritis (AIG) treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Autoimmune Gastritis (AIG) in the US, EU4 and the United Kingdom, and Japan?
- What are the Autoimmune Gastritis (AIG) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Autoimmune Gastritis (AIG)?
- How many therapies are in-development by each company for Autoimmune Gastritis (AIG) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Autoimmune Gastritis (AIG) treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Autoimmune Gastritis (AIG) therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Autoimmune Gastritis (AIG) and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Autoimmune Gastritis (AIG)?
- What are the global historical and forecasted markets of Autoimmune Gastritis (AIG)?
Reasons to buy Autoimmune Gastritis Market Report
- The report will help in developing business strategies by understanding trends shaping and driving the Autoimmune Gastritis (AIG) market
- Organize sales and marketing efforts by identifying the best opportunities for Autoimmune Gastritis (AIG) in the US, EU4(Germany, Spain, Italy, France) and the United Kingdom, and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Autoimmune Gastritis (AIG) market
- To understand the future market competition in the Autoimmune Gastritis (AIG) market
